Sep 28, 2017 7:00am EDT Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg
Sep 05, 2017 7:00am EDT Recro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017
Aug 21, 2017 7:00am EDT Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development